KoreK.LiowMDFACP, FAAN(He/Him)

Neurophysiology, Neurodegenerative

Neuroscience Chair & Principle Investigator, Hawaii Pacific Neuroscience, Clinical Professor of Med (Neurology), Graduate Faculty, Clinical & Translational Research, University of Hawaii John Burns School of Medicine

Join to view full profile

Dr. Liow is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Liow's full profile

Already have an account?

Office
2230 LILIHA ST., SUITE 104
104
Honolulu, HI 96817
Phone+1 808-261-4476

Fax+1 808-263-4476

Summary

Kore Liow, MD, FACP, FAAN is Founder & CEO; Neuroscience Chair of Hawaii Pacific Neuroscience. He is Clinical Professor of Medicine (Neurology), Graduate Faculty in Clinical & Translational Research at the University of Hawaii John A. Burns School of Medicine in Honolulu, Hawaii.

Having trained as a research neurologist at NINDS, NIH, he has devoted his life and spends majority of his time in neuroscience research carried out at Clinical Research Center where he has served as principal investigator (PI) for over 180 phase 0-IV clinical trials sponsored by the NIH, CDC and the industries. He is a nationally sought-after key opinion leader and published over 80 peer reviewed PubMed publications and served on NIH Review Study Section, Scientific Merit Review committees and advisory panel for CDC, AMA, AAN etc.

He has worked with sponsors/CROs on trial conception, design, development in submission to FDA trial approval, FDA IND application and submission of CSR (Clinical Study Report) to FDA. As PI, his performance matrix scores at 90% of patients randomized and 95% patients completing studies. His Clinical Research Center has a national reputation as a top-performing site and rapid site start up. He currently mentors over 20 medical students at the BRITL (Brain Research, Innovation & Translation Labs) & the Center for Neuroscience Diversity.

NIH Biosketch: https://www.ncbi.nlm.nih.gov/myncbi/1No_rVymWqZQp/bibliography/public/

https://hawaiineuroscience.com/doctor/dr-kore-kai-liow/

Hawaii ABC News Brain Doctor's Advice on Retiring with Purpose by Diane Ako - KI

Please join us to make a difference for Hawaii and the Global Neuroscience Commu

www.HawaiiNeurosciecne.com

Education & Training

National Capital ConsortiumFellowship, Clinical Neurophysiology, 1998 - 2000
University of Utah HealthResidency, Neurology, 1995 - 1998
Allegheny Health Network Medical Education Consortium (AGH)Internship, Internal Medicine, 1994 - 1995
St. George's University School of MedicineClass of 1993
Barry UniveristyPre-Med, 1987 - 1989
National junior collegePreMed, 1985 - 1987

Certifications & Licensure

HI State Medical License 2002 - 2026
UT State Medical License 1995 - 2002
PA State Medical License 2000 - 2000
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

Top Doctors (Neurology) Honolulu Magazine (Peer Nominated and Voted), 2012-2023
John M. Hardman, M.D. Award for Mentoring in Teaching (Faculty Recipient 2021) University of Hawaii John Burns School of Medicine, Honolulu, Hawaii, 2021
Faculty Teacher Appreciation Award, Department Psychiatry ACGME Residency Program Tripler Army Medical Center, Honolulu, Hawaii, 2019
Faculty Teaching Physician of the Year Award, Family Medicine Residency Program University of Hawaii John Burns School of Medicine, 2017
Faculty Teaching Physician of the Year, Family Medicine Residency Program University Hawaii John Burns School of Medicine, 2015
Physician of the Year (Hawaii) Adventist Health, 2013
CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2012-2013
Join now to see all

Clinical Trials

Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System. Start of enrollment: 2018 Feb 05
Active, not recruiting
A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age Start of enrollment: 2022 Aug 24
Recruiting
Phase 2
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease Start of enrollment: 2022 Jun 02
Active, not recruiting
Phase 3
Microdose Pharmacokinetic Study of PRX-P4-003 In Healthy Volunteers Start of enrollment: 2021 Feb 25
Completed
Early Phase 1
A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80 Start of enrollment: 2022 Apr 19
Recruiting
Phase 2
ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease Start of enrollment: 2020 Sep 28
Active, not recruiting
Phase 2, Phase 3
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine Start of enrollment: 2020 Jun 15
Recruiting
Phase 3
A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures Start of enrollment: 2020 Jan 27
Active, not recruiting
Phase 2
Roles: Contact
A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy Start of enrollment: 2021 Sep 15
Completed
Phase 3
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine Start of enrollment: 2020 Jun 30
Recruiting
Phase 3
A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular Pathology Start of enrollment: 2021 Jun 01
Terminated
Phase 2
Cenobamate Open-Label Extension Study for YKP3089C025 Start of enrollment: 2019 Aug 13
Enrolling by invitation
Phase 3
Study of Diazepam Buccal Film Administered in the Interictal and in the Ictal-Periictal States to Adults With Epilepsy Start of enrollment: 2017 May 25
Completed
Phase 2
Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's Disease Start of enrollment: 2017 Feb 17
Completed
Phase 1
Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies Start of enrollment: 2022 Mar 03
Completed
Phase 1, Phase 2
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease Start of enrollment: 2019 Mar 27
Active, not recruiting
Phase 3
A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity. Start of enrollment: 2021 Jun 23
Recruiting
Phase 4
Safety and Tolerability Study of Diazepam Buccal Film (DBF) in Subjects With Epilepsy Start of enrollment: 2018 Jan 23
Completed
Phase 3
Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension Start of enrollment: 2016 Feb 11
Completed
Phase 4
Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures Start of enrollment: 2018 Sep 21
Recruiting
Phase 3
Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures Start of enrollment: 2016 Aug 03
Completed
Phase 3
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations Start of enrollment: 2019 Sep 30
Active, not recruiting
Phase 3
A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy Start of enrollment: 2019 Jan 30
Active, not recruiting
Phase 2
A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures. Start of enrollment: 2013 Apr 03
Completed
Phase 3
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) Start of enrollment: 2021 May 18
Active, not recruiting
Phase 3
ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures Start of enrollment: 2022 Sep 01
Withdrawn
Phase 2
Assessing Clinical Outcomes in Alzheimer's Disease Agitation Start of enrollment: 2020 Dec 31
Completed
Phase 3
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part B Start of enrollment: 2019 Feb 28
Completed
Phase 1
A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET) Start of enrollment: 2021 Dec 06
Active, not recruiting
Phase 2
Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects Start of enrollment: 2021 Mar 01
Completed
Phase 2
Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy Start of enrollment: 2021 Sep 13
Completed
Phase 2
A Study to Assess the Pharmacokinetics (PK) and Safety of Staccato Alprazolam in Adolescent Study Participants With Epilepsy Start of enrollment: 2021 Apr 28
Completed
Phase 1
A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy Start of enrollment: 2020 Feb 27
Terminated
Phase 2
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Participants With Traumatic Brain Injury Start of enrollment: 2017 May 30
Completed
Phase 2
Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis Start of enrollment: 2019 Sep 17
Completed
Phase 3
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS) Start of enrollment: 2020 Aug 13
Recruiting
Phase 3
Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients Start of enrollment: 2020 Aug 14
Completed
Phase 1, Phase 2
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type Start of enrollment: 2020 Jul 08
Recruiting
Phase 3
An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab Start of enrollment: 2020 Jul 14
Active, not recruiting
Phase 3
A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis Start of enrollment: 2019 Jun 03
Completed
Phase 3
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS Start of enrollment: 2018 Dec 28
Recruiting
Phase 3
Study of Evobrutinib in Participants With RMS Start of enrollment: 2019 Sep 10
Terminated
Phase 3
Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine Start of enrollment: 2019 Oct 23
Terminated
Phase 2
A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy Start of enrollment: 2019 Mar 06
Terminated
Phase 3
Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects With Insomnia Disorder Start of enrollment: 2018 Jun 04
Completed
Phase 3
A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease Start of enrollment: 2016 Oct 20
Terminated
Phase 3
Addressing Dementia Via Agitation-Centered Evaluation Start of enrollment: 2017 Jul 13
Completed
Phase 2, Phase 3
Inpatient, Dose-Ranging Study of Staccato Alprazolam in Epilepsy With Predictable Seizure Pattern Start of enrollment: 2018 Mar 16
Completed
Phase 2
A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures Start of enrollment: 2017 Jul 07
Completed
Phase 4
Repeat Dose Safety Study of NRL-1 in Epilepsy Subjects Start of enrollment: 2016 Apr 11
Completed
Phase 3
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease Start of enrollment: 2017 Aug 03
Terminated
Phase 2, Phase 3
Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy Start of enrollment: 2018 Mar 20
Completed
Phase 2
A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD). Start of enrollment: 2016 Mar 22
Terminated
Phase 3
Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy Start of enrollment: 2018 Feb 12
Completed
Phase 2
Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy Start of enrollment: 2018 Aug 27
Terminated
Phase 2
Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease. Start of enrollment: 2017 Apr 10
Terminated
Phase 3
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia Start of enrollment: 2016 Jul 01
Terminated
Phase 3
ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease Start of enrollment: 2016 Aug 29
Terminated
Phase 3
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis Start of enrollment: 2016 Sep 20
Completed
Phase 3
Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor Start of enrollment: 2014 Mar 01
Completed
Phase 3
Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease Start of enrollment: 2014 Apr 07
Completed
Phase 3
Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures Start of enrollment: 2004 Jul 01
Completed
Phase 3
Bioavailability, Safety and Tolerability of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®) Start of enrollment: 2015 Jun 01
Terminated
Phase 2
A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets. Start of enrollment: 2014 Dec 01
Completed
Phase 3
Randomized Safety Study of CVT-301 Compared to an Observational Control Group Start of enrollment: 2015 Mar 01
Completed
Phase 3
Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes Start of enrollment: 2015 Mar 01
Completed
Phase 3
An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray. Start of enrollment: 2014 Dec 01
Terminated
Phase 2
Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil Start of enrollment: 2013 Oct 01
Completed
Phase 3
A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD Start of enrollment: 2022 Aug 03
Completed
Phase 3
A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease Start of enrollment: 2022 Dec 01
Recruiting
Phase 2
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures Start of enrollment: 2022 Nov 18
Recruiting
Phase 3
A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD Start of enrollment: 2023 Apr 01
Completed
Phase 2, Phase 3
A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD) Start of enrollment: 2022 Dec 27
Active, not recruiting
Phase 2
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy Start of enrollment: 2023 Jun 27
Recruiting
Phase 3
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy Start of enrollment: 2024 Mar 14
Recruiting
Phase 2, Phase 3
Roles: Contact
A Study Evaluating the Pharmacokinetics and Relative Bioavailability of Emraclidine Immediate-Release Tablets in Healthy Adult Participants Start of enrollment: 2023 Jul 19
Completed
Phase 1
Lu AF28996 in Participants With Parkinson's Disease (PD) Start of enrollment: 2020 Feb 26
Recruiting
Phase 1
RE104 Safety and Efficacy Study in Postpartum Depression Start of enrollment: 2024 Jun 14
Recruiting
Phase 2
Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 75 Years With gMG.
Join now to see all

Publications & Presentations

PubMed

82 citations
Aggression and Psychiatric Comorbidity in Children With Hypothalamic Hamartomas and Their Unaffected Siblings
Anne Austin Weissenberger, Mary Lynn Dell, Kore Liow, William H. Theodore, Carol M. Frattali
Journal of the American Academy of Child and Adolescent Psychiatry. 2001-06-01
44 citations
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.
Vera Bril, Artur Drużdż, Julian Grosskreutz, Ali A Habib, Renato Mantegazza
The Lancet. Neurology. 2023-05-01
49 citations
Final results from a Phase 3, long-term, open-label, repeat-dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy.
James W. Wheless, Ian Miller, R. Edward Hogan, Dennis J. Dlugos, Victor Biton
Epilepsia. 2021-08-21

Authored Content

Demographic recruitment bias of adults in United States randomized clinical trials by disease categories between 2008 to 2019: a systematic review and meta-analysisJanuary 2023
Disparities in Alzheimer Disease and Mild Cognitive Impairment Among Native Hawaiians and Pacific IslandersSeptember 2021
Buntanetap, a Novel Translational Inhibitor of Multiple Neurotoxic Proteins, Proves to Be Safe and Promising in Both Alzheimer’s and Parkinson’s PatientsOctober 2022
Native Hawaiian and Other Pacific Islanders’ Leading Risk Factors for Ischemic Stroke: A Comparative Ethnographic StudyMarch 2022
COVID-19 Is Changing Our Understanding of the Neuroscience of Viral Infections: What We Can Do to Prepare for the Future?December 2021
Variables Associated with Coronavirus Disease 2019 Vaccine Hesitancy Amongst Patients with Neurological DisordersAugust 2021
Effectiveness of dual migraine therapy with CGRP inhibitors and onabotulinumtoxinA injections: case seriesAugust 2021
Join now to see all

Press Mentions

Miami Dolphins Tua Tagovailoa Concussion Long Term side effects - Hawaii Neurologist Kore Liow, MDSeptember 14th, 2024
Seizure & Epilepsy Care in Hawaii: Where, What & How? Epileptologist Darren DuGas, MD from YaleSeptember 6th, 2024
2024 Alzheimer's TherapiesJuly 1st, 2024
Join now to see all

Grant Support

NIH COVID-19 Neuro Databank/Biobank (PI: A Troxel, Site PI: Liow)NINDS, NIH2022–Present
NIH NIA- Racial/Ethnic Disparities in the Alzheimer's Disease Link with Heart Disease and Stroke.NIH NIA2021–Present
CDC Assessing the Incidence and Prevalence of Epilepsy Populations in Rural Kansas (PI: Allen Hauser, Site PI: Liow)Centers for Disease Control and Prevention: GA, GA, US2015–Present
CDC Prevalence of Developmental Disabilities Among Children With Epilepsy in Rural Populations (PI D Linderman, Site PI: Liow)Centers for Disease Control and Prevention: GA, GA, US2015–Present
NIH Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) (PI: K Meador, Site PI: Liow)National Institute of Neurological Disorders and Stroke (Md., Md., US)2013–Present

Committees

Review Commitee, NIH Review Study Section, Scientific Merit Review, NINDS, NIH, Bethesda, MD, United States 2024 - Present
Advisory Review Panel, CDC Epidemiologic Studies & Surveillance Epilepsy, CDC, Atlanta, GA, United States 2007 - 2008

Research History

Principal InvestigatorServed as PI or site PI for more than 120 Phase 0,I,II,III and IV research studies in Neuroscience sponsored by the NIH, CDC and industries